Events

5th India Pharmaceutical Forum 2020

#
Session 1 : Welcome and Setting the Context- Mr Sudarshan Jain, IPA
#
Session 1 : Inaugural Address- Mr Satish Reddy, Dr Reddy's
#
Session 1 : Release of IPA Guidelines on Market Complaints
#
Session 3 : Quality and Patient Centricity- Mr Jeff Francer, AAM
#
Session 4 : CDER / OC / OMQ Update and Recent Cross Contamination Case Studies- Mr Jeff Francer, AAM
#
Session 4 : Surveillance Inspections and Recent Trends- Mr Jay Jariwala, USFDA (India)
#
Session 5 : Quality by Design for Robust Product- Dr James Pound, MHRA
#
Session 5 : Quality by Design for Robust Product- Mr Vipul Doshi, Cadila Healthcare
#
Session 6 : Culture Transformation - Best Practices- Dr Samantha Atkinson, MHRA
#
Session 6 : Culture Transformation - Best Practices- Ms Sue Schniepp, PDA
#
Session 6 : Culture Transformation - Best Practices- Mr Johnny Mikell, Lupin
#
Session 7 : Commitment to Quality in Pharmaceutical Development and Commercial Manufacturing- Dr Stelios Tsinontides, USFDA
#
Session 7 : Cost of Quality- Dr Ranjana Pathak, Cipla
#
Session 8 : Global Best Practices in Capability Building- Mr Jaidev Rajpal, McKinsey & Co.
#
Session 8 : Digital Technologies in Pharma Operations for Improved Quality- Mr Matthias Spiegl, McKinsey
#
Session 9 : Nitrosamine Impurities - Current Status and Expectations- Dr Declan Byrne, EDQM
#
Session 9 : Nitrosamine Impurities - Current Status and Expectations- Dr Milind Joshi, J B Chemicals
  • # 27 February 2020 - 28 February 2020
  • # JW Marriott, Mumbai